Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Tretinoin improves the anti-cancer response to cyclophosphamide, in a model-selective manner

Fig. 3

The efficacy of combination tretinoin–CY treatment is both CD8+ and CD4+ T cell dependent. (A-B) Survival of mice inoculated with AB1-HA and treated with 200 mg/kg CY with or without tretinoin. Mice were depleted of CD8 (B) or CD4 (C) T cells using 100 µg αCD4 or αCD8 i.p., 3days prior to inoculation and depletion was maintained throughout the experiment. Mice were dosed daily with 10 mg/kg tretinoin, beginning 3 days before CY for nine total doses. (C) Enrichment analysis of CD4 tretinoin-associated gene set in complete responders or progressors to CY. Positive NES indicates a gene set is enriched in CR. Significance for survival analysis was determined using the Mantel-Cox log-rank test. *p < 0.05 **p < 0.01. n = 5 for tretinoin, αCD8 + CY and αCD8 + CY + tretinoin, n = 10 for all other groups

Back to article page